GalNAc-Targeted C3 RNAi Agents for Durable Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement-mediated renal diseases and other complement-related disorders, such as IgA nephropathy and C3 glomerulopathy, are limited, with existing therapies requiring frequent administration, having suboptimal efficacy, and lacking a safe and durable mechanism to inhibit C3 and the complement cascade proximally.
Innovation Solution
Development of RNAi agents comprising modified sense and antisense strands, linked to a targeting ligand like N-acetyl-galactosamine, to inhibit C3 gene expression, which are administered less frequently and provide a safer, more effective therapeutic option.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies (eculizumab, ravulizumab) are used to inhibit C5, then complement-mediated diseases can be treated, but frequent intravenous infusion (every 2 weeks to 2 months) is required and effector pathways are not fully blocked
Solution Approach 1:
The RNAi agent is administered in advance to suppress C3 gene expression before complement activation occurs, preventing the formation of C3 convertase and downstream effector pathways. This preliminary genetic-level intervention eliminates the need for repeated protein-level inhibition.
Solution Approach 2:
The patent uses N-acetyl-galactosamine as a targeting ligand that mediates specific binding of the RNAi agent to hepatocytes, enabling prolonged residence time and sustained C3 suppression. This intermediary facilitates durable therapeutic effect without frequent readministration.
2Reliability
If pegcetacoplan is used to inhibit C3, then proximal complement pathway is blocked, but subcutaneous infusion pump administration twice weekly is required
Solution Approach 1:
The RNAi agent self-amplifies its effect by suppressing C3 mRNA transcription continuously, maintaining therapeutic levels without requiring external reinforcement through frequent dosing. The modified nucleotides enable the agent to persist and function autonomously in the body.
Solution Approach 2:
A single administration of the RNAi agent preliminarily establishes sustained C3 suppression by targeting gene expression at the transcriptional level, eliminating the need for repeated pump-based infusions and improving patient convenience.
3Adaptability or versatility
If existing therapies are used for IgA nephropathy and C3 glomerulopathy, then treatment options are available, but substantial unmet medical need remains due to limitations in efficacy and durability
Solution Approach 1:
The patent changes the therapeutic parameter from protein-level inhibition (monoclonal antibodies, peptides) to gene-level suppression (RNAi), achieving more durable and potent C3 inhibition. This parameter change transforms transient therapeutic effects into sustained genetic silencing.
Solution Approach 2:
The RNAi agent combines modified sense and antisense strands with N-acetyl-galactosamine targeting ligand and modified nucleotides to create a composite therapeutic molecule that achieves both potent C3 suppression and prolonged durability, overcoming limitations of existing monotherapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agents effectively reduce C3 gene expression, offering a highly active, durable, and safe treatment for complement-related diseases with improved patient compliance by requiring infrequent administration.
Implementation Method 1
RNA interference (RNAi) agents, e.g., double stranded RNAi agents or interfering RNA molecules, for inhibition of Complement Component C3 (C3) gene expression
Implementation Method 2
wherein all or substantially all of the nucleotides of the antisense strand and/or the sense strand are modified nucleotides
Data Source
AI summary
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents or siRNAs, able to inhibit Complement Component C3 (C3) gene expression. Also disclosed are pharmaceutical compositions that include C3 RNAi agents and methods of use thereof. The C3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the C3 RNAi agents in vivo provides for inhibition of C3 gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by C3 gene expression, including IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and/or other complement-mediated renal diseases.